Table 2.
Industry Involvement Status and Trial Design and Outcome
| Trial Variable |
No funding (n= 70) |
Funding only (n = 41) |
Collaboration (n = 111) |
|||||
|---|---|---|---|---|---|---|---|---|
| No. (%) | RR (95% CI) | No. (%) | RR (95% CI) | P Value | No. (%) | RR (95% CI) | P Value | |
| ITT analysis |
39 (55·7) | 1 (ref) | 21 (51·2) | 0·92 (0·64–1·32) | 0·70 | 81 (73·0) | 1·31 (1·03–1·65) | 0·023 |
| Placebo Control used |
9 (12·9) | 1 (ref) | 7 (17·1) | 1·33 (0·53–3·30) | 0·58 | 51 (45·9) | 3·57 (1·88–6·79) | <0·001 |
| Patient blinded |
11 (15·7) | 1 (ref) | 7 (17·1) | 1·09 (0·46–2·58) | 0·99 | 53 (47·7) | 3·04 (1·71–5·41) | <0·001 |
| Clinician blinded |
10 (14·3) | 1 (ref) | 7 (17·1) | 1·20 (0·49–2·90) | 0·79 | 53 (47·7) | 3·34 (1·82–6·13) | <0·001 |
| Outcome assessor blinded |
9 (12·9) | 1 (ref) | 11 (26·8) | 2·09 (0·95–4·61) | 0·077 | 43 (38·7) | 3·01 (1·57–5·79) | <0·001 |
| Primary endpoint: OS |
14 (20·0) | 1 (ref) | 10 (24·4) | 1·22 (0·60–2·49) | 0·64 | 28 (25·2) | 1·26 (0·72–2·22) | 0·47 |
| Positive result |
37 (52·9) | 1 (ref) | 18 (43·9) | 0·83 (0·55–1·25) | 0·43 | 64 (57·7) | 1·09 (0·84–1·43) | 0·54 |
ITT=intention-to-treat; OS=Overall survival; PFS=progression-free survival; DFS=disease-free survival